The Daily Buyout
UndisclosedStrategic acquisitionHealthcare & Life SciencesCompleted

PTC Therapeutics Completes Acquisition of Sangamo's ST-920 Gene Therapy

PTC Therapeutics completed its acquisition of ST-920, a BLA-stage AAV gene therapy for Fabry disease, from Sangamo Therapeutics.

Read the full coverage, free

We only link to sources you can read without a subscription. How we check.

More Healthcare & Life Sciences deals